This is analogous to the evidence pathway followed for liraglutide (LEADER trial, NEJM 2016) and semaglutide (SUSTAIN-6 trial, NEJM 2016), which established cardiovascular benefit for those agents only after large, long-term CVOTs reported [6] The heart rate increase warrants ongoing surveillance, particularly in patients with pre-existing cardiac conditions Phase 3 trials are currently underway (see ClinicalTrials.gov and the EU Clinical Trials Information System, CTIS, for registered studies)
Retatrutide reduces liver fat through overall metabolic improvement and caloric deficit
Many people find that eating smaller meals more frequently works better than trying to eat three large meals
The STEP 1 trial published results in the New England Journal of Medicine in February 2021, showing 14.9% weight loss at 68 weeks (Wilding et al., NEJM 2021)
Existing evidence indicates that eating disorders can increase the risk of diabetes, obesity, hypertension, hypertriglyceridemia, headache, back pain, and other chronic metabolic diseases
Short-form complaints are a less burdensome way for plaintiffs to file a case
